Sea breezes and sunshine for Diaceutics cyclists | Diaceutics

Sea breezes and sunshine for Diaceutics cyclists

December 11th, 2017

If you’re going to take part in a charity cycle race for cancer, then where better than California? This was the sunny setting for Ewelina Golebiewska and John McNamara from Diaceutics as they joined Team Pfizer in November 2017 on the two-day Padres Pedal the Cause event.

The scenery was amazing and the atmosphere even better, plus we had super supportive crowds cheering us on, recalled Ewelina. That’s not to say it was easy. An 88-mile hilly ride on the Saturday followed by 66 miles into the coastal head winds the day after is enough to test the strongest cyclist, but they all loved it and were pushed on by adrenaline, excitement, team spirit and a San Diego sea breeze. It was definitely a challenge, especially that one big 600m climb, but what does that matter when you get to cycle across the Coronado bridge on one of only two days a year it’s opened to cyclists? John and Ewelina settled into the Pfizer team like a companion diagnostic fits its therapy, and they all worked together to reach their goal – to raise as much money as possible for cancer research projects in the San Diego area. They certainly achieved that, with the two Diaceutics cyclists adding an impressive $3149 to the cause.

More inspiring than the ocean view though, was the feeling that everyone was doing their bit for cancer research. “The hundreds of people taking part in the race are all directly involved with cancer in their daily lives. They have careers behind the scenes in research, hospitals and big cancer centres, or work directly with patients,” said Ewelina. “It was fantastic to all be doing something so positive outside work as well.”

With 100 per cent of donations going to fund ongoing discoveries in the fight against cancer, Ewelina is already looking forward to her next Team Diaceutics cycling challenge. Well done, from all at Diaceutics.

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications